New Non-Invasive Ultrasound Device

Spencer Technologies Begins Shipping a New Digital Transcranial Doppler

That Better Identifies Conditions Contributing to Stroke



Apr 10, 2001, 01:00 ET from Spencer Technologies

    SEATTLE, April 10 /PRNewswire/ -- Spencer Technologies has begun shipping
 its first major product, the TCD 100M, a digital transcranial Doppler (TCD).
 The ultrasound device features a unique, patented display that offers greater
 ease of use over current technology and has significant technical advantages.
     The TCD 100M Digital Doppler features patented FlowTrax(TM) signal
 acquisition and display technology.  This allows novice and expert users alike
 to easily identify the location of blood flow within the brain.
     Reactions at medical professional meetings this year have been very
 encouraging.  The company has received numerous requests for product
 demonstrations, and is in the process of ramping up its U.S. sales effort, as
 well as preparing for sales in Europe this summer.
     The company's promotional strategy is geared toward replacing its
 competitors' worldwide, installed base of approximately 15,000 units
 containing the older, analog TCD technology. This will significantly expand
 the overall market by encouraging wider utilization of the digital TCD 100M
 which is easier to learn and use.
     According to Dr. Andrei Alexandrov, a neurologist on the Stroke Treatment
 Team at the University of Texas - Houston Medical School and Principal
 Investigator for the Phase II CLOTBUST randomized clinical trial of
 ultrasound-enhanced thrombolysis with TPA for stroke, "It (the TCD 100M) may
 be the first technology to make TCD easy-to-use for clinicians, particularly
 in the emergency situations or at bedside, and to help develop
 operator-independent TCD devices for non-invasive diagnosis and monitoring."
     Dr. Andrew Demchuk, a leading neurologist at the University of Calgary and
 a recent TCD 100M purchaser comments, "Things are going great!  I've found
 training others how to use TCD much easier.  What a breeze!  We are already
 uncovering findings with Power M-Mode (Flowtrax) never before seen with
 standard TCD."
     Spencer Technologies has four additional products in its pipeline, all
 based on this digital TCD platform. These products address the detection,
 prevention, and treatment of conditions leading to stroke, brain hemorrhage,
 pulmonary embolism, and deafness.
     Spencer Technologies is dedicated to significantly improving healthcare
 through non-invasive technologies for diagnosis, monitoring, and therapy.  It
 is an integrated patient service, clinical research, R&D, and manufacturing
 company marketing innovative products.
 
 

SOURCE Spencer Technologies
    SEATTLE, April 10 /PRNewswire/ -- Spencer Technologies has begun shipping
 its first major product, the TCD 100M, a digital transcranial Doppler (TCD).
 The ultrasound device features a unique, patented display that offers greater
 ease of use over current technology and has significant technical advantages.
     The TCD 100M Digital Doppler features patented FlowTrax(TM) signal
 acquisition and display technology.  This allows novice and expert users alike
 to easily identify the location of blood flow within the brain.
     Reactions at medical professional meetings this year have been very
 encouraging.  The company has received numerous requests for product
 demonstrations, and is in the process of ramping up its U.S. sales effort, as
 well as preparing for sales in Europe this summer.
     The company's promotional strategy is geared toward replacing its
 competitors' worldwide, installed base of approximately 15,000 units
 containing the older, analog TCD technology. This will significantly expand
 the overall market by encouraging wider utilization of the digital TCD 100M
 which is easier to learn and use.
     According to Dr. Andrei Alexandrov, a neurologist on the Stroke Treatment
 Team at the University of Texas - Houston Medical School and Principal
 Investigator for the Phase II CLOTBUST randomized clinical trial of
 ultrasound-enhanced thrombolysis with TPA for stroke, "It (the TCD 100M) may
 be the first technology to make TCD easy-to-use for clinicians, particularly
 in the emergency situations or at bedside, and to help develop
 operator-independent TCD devices for non-invasive diagnosis and monitoring."
     Dr. Andrew Demchuk, a leading neurologist at the University of Calgary and
 a recent TCD 100M purchaser comments, "Things are going great!  I've found
 training others how to use TCD much easier.  What a breeze!  We are already
 uncovering findings with Power M-Mode (Flowtrax) never before seen with
 standard TCD."
     Spencer Technologies has four additional products in its pipeline, all
 based on this digital TCD platform. These products address the detection,
 prevention, and treatment of conditions leading to stroke, brain hemorrhage,
 pulmonary embolism, and deafness.
     Spencer Technologies is dedicated to significantly improving healthcare
 through non-invasive technologies for diagnosis, monitoring, and therapy.  It
 is an integrated patient service, clinical research, R&D, and manufacturing
 company marketing innovative products.
 
 SOURCE  Spencer Technologies